ArticleCancers2026

Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study.

Shilong Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.